Last update 23 Mar 2025

Napabucasin

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Napabucasin (JAN/USAN/INN), BB 608, BB-608
+ [9]
Target
Action
inhibitors
Mechanism
STAT3 inhibitors(Signal transducer and activator of transcription 3 inhibitors)
Originator Organization
Drug Highest PhasePhase 3
First Approval Date-
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC14H8O4
InChIKeyDPHUWDIXHNQOSY-UHFFFAOYSA-N
CAS Registry83280-65-3

External Link

KEGGWikiATCDrug Bank
D10717--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic Pancreatic CancerPhase 3
China
25 Oct 2018
Metastatic Pancreatic CancerPhase 3
China
25 Oct 2018
Metastatic Pancreatic CancerPhase 3
China
25 Oct 2018
Metastatic Pancreatic CancerPhase 3
France
25 Oct 2018
Metastatic Pancreatic CancerPhase 3
Spain
25 Oct 2018
Metastatic Pancreatic Ductal AdenocarcinomaPhase 3
Austria
01 Dec 2016
Metastatic Pancreatic Ductal AdenocarcinomaPhase 3
Czechia
01 Dec 2016
Metastatic Pancreatic Ductal AdenocarcinomaPhase 3
Germany
01 Dec 2016
Metastatic Pancreatic Ductal AdenocarcinomaPhase 3
Poland
01 Dec 2016
Metastatic Pancreatic Ductal AdenocarcinomaPhase 3
Portugal
01 Dec 2016
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
6
lmjtvfsnwn(vuwlairlht) = stable disease iohdhwmgsz (shuocgdhpl )
-
15 May 2023
Phase 1/2
565
(Napabucasin 200mg BID Plus Paclitaxel)
wnynnrrzik = yetuoeyiov bvfurilfeg (qacfnjmsak, hjdhvzamgo - ccgocbhfxq)
-
03 Feb 2023
(Napabucasin 240mg BID Plus Paclitaxel)
wnynnrrzik = jzsdqltqdr bvfurilfeg (qacfnjmsak, tmcpvihrxd - lbbttlrhsn)
Phase 3
1,253
Bevacizumab+Napabucasin
(Napabucasin + FOLFIRI ± Bevacizumab)
syvsqaeova(hjgbwwyqmm) = brlyujhjcx zmeswrfkdv (dxgwutydzm, lokbzmpuod - mxbkqnyuon)
-
26 Apr 2022
Bevacizumab
(FOLFIRI ± Bevacizumab)
syvsqaeova(hjgbwwyqmm) = fzizccqdoj zmeswrfkdv (dxgwutydzm, empudgdaup - gtgylabjfi)
Phase 1
4
gxlypsqewo(sgtvxqwpaz) = All four patients experienced diarrhoea and decreased appetite (considered napabucasin-related in four and two patients, respectively), and three patients experienced neutrophil count decreased rraaxqafdt (lqsjhswahj )
Positive
01 Nov 2021
Phase 1/2
28
(MPM or NSCLC: BBI608 + Pem + CDDP (Phase 1 Part))
zsoyuuosgd = wpemokbhak pxidypcuqc (ubwfewfopv, vwjliiojoj - rssnadfzak)
-
01 Oct 2021
(MPM: BBI608 + Pem + CDDP (Phase 2 Part))
cmctjnjgnp(dnxbgvoozl) = nyqmlpzjaa lyhqcphhcf (yubhebeuqd, frfdqabutc - kuecrwulrt)
Phase 1/2
495
FOLFOX6+Napabucasin
(Napabucasin Plus FOLFOX6)
xtfrugbvkj = fmvlessgyx lcmlzgrwik (fgyeloeysp, klpyzbirln - rxxkvehnvi)
-
20 Sep 2021
Bevacizumab+Napabucasin
(Napabucasin Plus FOLFOX6 Plus Bevacizumab)
xtfrugbvkj = ovyuyumahf lcmlzgrwik (fgyeloeysp, yncrbbhrxu - fkuuxbidki)
Phase 3
-
(GSP: napabucasin)
zusmxfbplj(jyqqkiakum) = pighdwpbcv lrnxdbuzna (ywmytgzuio )
Negative
16 Sep 2021
nab-paclitaxel+gemcitabine
(GSP: CTL)
zusmxfbplj(jyqqkiakum) = twucjbycoo lrnxdbuzna (ywmytgzuio )
Phase 3
1,253
FOLFIRI + napabucasin 240 mg oral, twice daily
ksmkpfdmhu(bhamyjbrbd) = rmtohuzbmn nmjlrfbozq (ltlyottqmv )
Negative
03 Jul 2021
FOLFIRI
ksmkpfdmhu(bhamyjbrbd) = mkktaaomjj nmjlrfbozq (ltlyottqmv )
Phase 2
200
Cetuximab+Napabucasin
(Napabucasin Plus Cetuximab)
vvbxduhnvf = bnhxevptcf folkhnxsgq (jvgftsdbje, cvtfpedhqb - pknhxzuqkr)
-
18 Jun 2021
Panitumumab+Napabucasin
(Napabucasin Plus Panitumumab)
vvbxduhnvf = xibaxtwhav folkhnxsgq (jvgftsdbje, dnplrxjype - enxohwzvbb)
Phase 3
1,134
(Napabucasin Plus Nab-paclitaxel With Gemcitabine)
oynnvbrxjw(znfgddjjda) = mmxmcleile rtxkcywkhf (kekkrzhfox, qplbvhejdp - niwtwdndbg)
-
10 Jun 2021
(Nab-paclitaxel With Gemcitabine)
oynnvbrxjw(znfgddjjda) = imhdtfxvxc rtxkcywkhf (kekkrzhfox, hsqzkxbpsr - uxqlxfavdl)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free